Abstract:Annexin IV (ANXA4) is highly expressed in ovarian clear cell carcinoma (OCCC); however, its underlying molecular mechanism in OCCC remains unknown. The present study aimed to identify the molecule that ANXA4 may act on and to determine its underlying molecular mechanism. Immunohistochemistry, co-immunoprecipitation and western blotting were performed to detect the expression and interaction of ANXA4, and its associated proteins. Furthermore, MTT assay, flow cytometry, western blotting and gene expression profile enrichment analysis were performed to identify the potential role and molecular mechanism of ANXA4 in OCCC. The results demonstrated that ANXA4 and nuclear factor-kappa-light-chain-enhancer of activated B cells (NF-kappa B) p50 nuclear expression levels were significantly higher in OCCC tissues compared with other subtypes of ovarian cancer, such as serous and mucinous. In addition, a significantly positive correlation was observed between ANXA4 and NF-kappa B p50 expression in OCCC; however, the expression levels of mutant p53 and ANXA4 were negatively correlated in a linear manner. These results suggest that ANXA4 and NF-kappa B p50 may be potential independent risk factors for poor prognosis. ANXA4 and NF-kappa B p50 were demonstrated to interact and their expression was co-localized. The cBioPortal database was used to construct a protein-protein interaction network between ANXA4, NF-kappa B p50 and p53, and functional pathway analysis indicated that the genes were predominantly enriched in the cell cycle and during apoptosis. Transfection of the ANXA4 gene increased the expression of NF-kappa B p50, as well as its downstream targets, Cyclin D1 and B-cell lymphoma-2 (Bcl-2). Furthermore, transfection of the ANXA4 gene increased proliferation and decreased apoptosis of OCCC cells. Treatment with the NF-kappa B inhibitor, BAY 11-7082, decreased Cyclin D1 and Bcl-2 expression levels. Collectively, the results of the present study suggest that wild p53 activates ANXA4 transcription, promotes its expression and enhances NF-kappa B p50 and ANXA4 interaction. This in turn activates the NF-kappa B signaling pathway, promotes cell cycle progression and inhibits apoptosis, thus contributing to the malignant progression of OCCC. Thus, ANXA4 and NF-kappa B p50 may be used as prognostic biomarkers, and may be molecular therapeutic targets in OCCC.

4.1N Suppresses Hypoxia-Induced Epithelial-Mesenchymal Transition in Epithelial Ovarian Cancer Cells.

Defective Expression of Protein 4.1N is Correlated to Tumor Progression, Aggressive Behaviors and Chemotherapy Resistance in Epithelial Ovarian Cancer

Loss of 4.1N in epithelial ovarian cancer results in EMT and matrix-detached cell death resistance

CRMP4 Suppresses Cervical Cancer Cell Proliferation and EMT Through the Wnt/β-catenin Pathway

Notch1 Affects Chemo-resistance Through Regulating Epithelial-Mesenchymal Transition (EMT) in Epithelial Ovarian Cancer Cells

Eif4e Binding Protein 1 Expression is Associated with Clinical Survival Outcomes in Colorectal Cancer

Long Non-Coding RNA AOC4P Suppresses Epithelial Ovarian Cancer Metastasis by Regulating Epithelial-Mesenchymal Transition

Natural Antisense Transcript of Hypoxia-Inducible Factor 1 Regulates Hypoxic Cell Apoptosis in Epithelial Ovarian Cancer

LINC01088 Inhibits Tumorigenesis of Ovarian Epithelial Cells by Targeting Mir-24-1-5p

Long Non-Coding RNA SLC25A21-AS1 Inhibits the Development of Epithelial Ovarian Cancer by Specifically Inducing PTBP3 Degradation

OSR1 downregulation indicates an unfavorable prognosis and activates the NF-κB pathway in ovarian cancer

p53 and ANXA4/NF-B p50 complexes regulate cell proliferation, apoptosis and tumor progression in ovarian clear cell carcinoma

NADPH Oxidase 4 Promotes Hypoxia-induced Epithelial-to-mesenchymal Transition via Histone Modification in Pancreatic cancer

Overexpression of STAT4 under hypoxia promotes EMT through miR-200a/STAT4 signal pathway

Overexpression of NPTX2 Promotes Malignant Phenotype of Epithelial Ovarian Carcinoma <i>via</i> IL6-JAK2/STAT3 Signaling Pathway Under Hypoxia

TNNC1 knockout reverses metastatic potential of ovarian cancer cells by inactivating epithelial-mesenchymal transition and suppressing F-actin polymerization

Linker Histone H1.4 Inhibits the Growth, Migration and EMT Process of Non-Small Cell Lung Cancer by Regulating ERK1/2 Expression

Downregulation of RIPK4 Expression Inhibits Epithelial-Mesenchymal Transition in Ovarian Cancer through IL-6

OCT4 induces EMT and promotes ovarian cancer progression by regulating the PI3K/AKT/mTOR pathway

OTX1 Silencing Suppresses Ovarian Cancer Progression Through Inhibiting the JAK/STAT Signaling.

Oncogenic Role of NUPR1 in Ovarian Cancer